When would you recommended restarting biologic medications in an active RA patient after treatment with monoclonal antibodies, convalescent plasma or antiviral medications for a COVID-19 infection?

As rheumatologists, we are accustomed to medical decision making in data free zones. This is what we face here too. There are no studies that have directly addressed these issues- nonetheless, the likelihood of meaningful drug interactions between a biological drug for RA and these various anti-viral therapies would be slight to nil for most products.

My main concern in these situations is whether my patient has sufficiently recovered from their SARS Covid -19 infection to safely return to their...